Trastuzumab Deruxtecan in Non-Small-Cell Lung Cancer. Reply
- PMID: 35507496
- PMCID: PMC11285070
- DOI: 10.1056/NEJMc2202305
Trastuzumab Deruxtecan in Non-Small-Cell Lung Cancer. Reply
Conflict of interest statement
Since publication of their article, the authors report no further potential conflict of interest.
Comment on
-
Trastuzumab Deruxtecan in Non-Small-Cell Lung Cancer.N Engl J Med. 2022 May 5;386(18):1769-1770. doi: 10.1056/NEJMc2202305. N Engl J Med. 2022. PMID: 35507494 Free PMC article. No abstract available.
-
Trastuzumab Deruxtecan in Non-Small-Cell Lung Cancer.N Engl J Med. 2022 May 5;386(18):1770. doi: 10.1056/NEJMc2202305. N Engl J Med. 2022. PMID: 35507495 No abstract available.
References
-
- Powell CA, Modi S, Iwata H, et al. Abstract CT167: pooled analysis of drug-related interstitial lung disease (ILD) in 8 single-arm trastuzumab deruxtecan (T-DXd) studies. Cancer Res 2021; 81:Suppl 13:CT167. abstract.
-
- Swain SM, Nishino M, Lancaster LH, et al. Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)–related interstitial lung disease — focus on proactive monitoring, diagnosis, and management. Cancer Treat Rev 2022. January 14 (Epub ahead of print). - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical